By Terry Chrisomalis Oncolytics Biotech, Inc. (USA) On July 6, 2015 shares of Oncolytics Biotech, Inc.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that a series of oral and poster presentations are being made by the Company’s research collaborators at …
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that all nominees listed in the management information circular dated May 6, 2015 were elected as directors at …
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) provided an update on its planned registration program for REOLYSIN®, its proprietary formulation of the human reovirus, at its Annual …
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that following submission to the U.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, announced that the European …
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that …
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that Dr.
Oncolytics Biotech,® Inc. (USA) (NASDAQ:ONCY) announced that it has submitted an application for Orphan Drug Designation to the U.
Oncolytics Biotech® Inc. (USA) (NASDAQ:ONCY) today announced that Dr.